Table. Demographic and Clinical Characteristics of 110 Infants.
| Variable | Magnesium Administration | P Value | |||
|---|---|---|---|---|---|
| 2002-2008 | 2009-2014 | ||||
| No (n = 27) | Yes (n = 15) | No (n = 26) | Yes (n = 42) | ||
| Maternal and neonatal variables | |||||
| Multiple gestationa | 9 (33) | 6 (40) | 10 (39) | 13 (31) | .89 |
| Clinical chorioamnionitisa | 10 (37) | 0 (0) | 2 (8) | 6 (14) | .003 |
| PPROMa | 13 (48) | 4 (27) | 8 (31) | 21 (50) | .23 |
| Magnesium exposure duration, hb | 0 | 25 (13-59)c | 0 | 28 (4-52)c | .001 |
| Gestational age at delivery, wkb | 25 (24-28) | 26 (23-29) | 27 (24-29) | 25 (24-28) | .64 |
| Infant male sexa | 19 (70) | 7 (47) | 13 (50) | 24 (57) | .37 |
| Infant nonwhite race/ethnicitya | 6 (22) | 2 (13) | 9 (35) | 12 (29) | .46 |
| Birth weight, gb | 769 (602-1160) | 745 (567-879) | 722 (543-999) | 838 (609-1046) | .39 |
| Intraventricular hemorrhagea | 15 (56) | 6 (40) | 16 (62) | 25 (60) | .41 |
| Bronchopulmonary dysplasiaa | 15 (56) | 10 (67) | 19 (73) | 36 (86) | .049 |
| Infant neurological outcomed | |||||
| Age at CP diagnosis, mob | 29 (22-41) | 26 (20-33) | 23 (14-34) | 21 (15-26) | .03 |
| GMFCS levela | |||||
| I | 13 (48) | 7 (47) | 15 (58) | 22 (52) | .42 |
| II | 1 (4) | 2 (13) | 5 (19) | 8 (19) | |
| III | 3 (11) | 3 (20) | 3 (12) | 1 (2) | |
| IV | 4 (15) | 1 (7) | 1 (4) | 6 (14) | |
| V | 6 (22) | 2 (13) | 2 (8) | 5 (12) | |
Abbreviations: CP, cerebral palsy; GMFCS, Gross Motor Function Classification System; PPROM, preterm premature rupture of membranes.
a
Data presented as number (percentage) and analyzed using the multinomial χ2 test.
b
Data presented as median (interquartile range) and analyzed using the Kruskal-Wallis analysis of variance on ranks values.
c
P < .05 compared with infants who were not exposed to magnesium during the same period.
d
Assessed by investigators (B.S., B.K., and I.B.) unaware of antenatal magnesium exposure.